Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022Yi‐Chu Chen, Jyh‐Ming Liou, Mei‐Jyh Chen et al.|Gastroenterology|2024Cited by 449
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trialJyh‐Ming Liou, Ming‐Shiang Wu, Chieh‐Chang Chen et al.|The Lancet|2012Cited by 268
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trialJyh‐Ming Liou, Ming‐Shiang Wu, Chieh‐Chang Chen et al.|The Lancet Infectious Diseases|2019Cited by 206
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trialJyh‐Ming Liou, Ming‐Shiang Wu, Yu-Jen Fang et al.|The Lancet|2016Cited by 202